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Abstract:  134 
Elevated blood pressure is the leading heritable risk factor for cardiovascular disease 135 
worldwide. We report genetic association of blood pressure (systolic, diastolic, pulse 136 
pressure) among UK Biobank participants of European ancestry with independent replication 137 
in other cohorts, leading to discovery and validation of 107 novel loci. We also identify new 138 
independent variants at 11 previously reported blood pressure loci. Combined with results 139 
from a range of in-silico functional analyses and wet bench experiments, our findings highlight 140 
new biological pathways for blood pressure regulation enriched for genes expressed in 141 
vascular tissues and identify potential therapeutic targets for hypertension. Results from 142 
genetic risk score models raise the possibility of a precision medicine approach through early 143 
lifestyle intervention to offset the impact of blood pressure raising variants on future 144 
cardiovascular disease risk.  145 
 146 
 147 
 148 
  149 
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Elevated blood pressure is a strong, heritable and modifiable driver of risk for stroke and 150 
coronary artery disease and a leading cause of global mortality and morbidity1,2.  In most 151 
populations blood pressure rises with age and by older ages over 50% of the population has 152 
hypertension3,4. Raised blood pressure is heritable and arises from a complex interplay of 153 
lifestyle exposures and genetic background5-8. To date, studies including genome-wide meta-154 
analyses of up to 2.5 million HapMap imputed variants across multiple studies, and analyses 155 
of bespoke or exome content, have identified 163 genetic variants of mostly modest or weak 156 
effect on blood pressure at 122 loci9-13. Here, we report association analyses between three 157 
blood pressure traits (systolic, diastolic and pulse pressure) and genetic variants among the 158 
first ~150,000 UK Biobank participants, with independent replication in large international 159 
consortia and other cohorts, providing new biological insights into blood pressure regulation. 160 
 161 
UK Biobank is a prospective cohort study of 500,000 men and women aged 40-69 years with 162 
extensive baseline phenotypic measurements according to a standardized protocol (including 163 
blood pressure by a semi-automated device: Omron HEM-7015IT digital blood pressure 164 
monitor), stored biological samples (including DNA)14, and follow-up by electronic health 165 
record linkage15. Participants were genotyped using a customised array (including GWAS and 166 
exome content) and with genome-wide imputation based on 1000 Genomes and UK10K 167 
sequencing data16,17. 168 
 169 
Our study design is summarised in Fig. 1. Briefly, of the 152,249 UK Biobank participants with 170 
genotype data, after quality measures and exclusions (see Methods Online), we study 171 
140,886 unrelated individuals of European ancestry with two seated clinic blood pressure 172 
measurements (Supplementary Table 1). We carry out genome-wide association study 173 
(GWAS) analyses of systolic, diastolic and pulse pressure using single-variant linear regression 174 
under an additive model, based on ~9.8 million single nucleotide variants (SNVs) with minor 175 
allele frequency (MAF) >1% and imputation quality score (INFO) >0.1. We then consider for 176 
replication SNVs with P <1x10-6 and take forward the sentinel SNV (i.e. with lowest P-value) 177 
at each locus, with a locus being defined by linkage disequilibrium (LD) r2 < 0.2, within a 1Mb 178 
interval. We similarly analyse exome content for variants with MAF >0.01%, including rare 179 
variants, taking into replication the sentinel SNV (P < 1x10-5) from loci that are non-180 
overlapping (r2 <0.2) with the GWAS findings. Overall we took the sentinel SNVs from 240 loci 181 
into replication (r2 < 0.2 and >500kb from previously reported blood pressure SNVs and not 182 
annotated to previously reported blood pressure genes): 218 from GWAS and 22 from the 183 
exome analysis (GWAS variants from an additional 17 novel loci could not be taken into 184 
replication due to the absence of the variant or a proxy in the replication resources 185 
(Supplementary Tables 2 and 3).  186 
 187 
The replication resources comprise a large BP meta-analysis consortium and further cohorts 188 
with 1000 Genomes data for the GWAS findings (Supplementary Table 4), and large blood 189 
pressure exome consortia meta-analyses, both with individuals of European ancestry. We use 190 
P <5x10-8 to denote genome-wide significance in the combined (discovery and replication) 191 
meta-analyses, also requiring evidence of support (P < 0.01) in the replication data alone and 192 
concordant direction of effect. Additionally, we take forward for replication potential 193 
secondary signals at 51 previously reported blood pressure loci (excluding the HLA region). 194 
We note that the replication P-value threshold of P < 0.01 is more stringent than a range of 195 
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thresholds calculated according to False Discovery Rate (FDR) which gives FDR thresholds of 196 
0.03 < P < 0.04 (see Supplementary Methods). 197 
To better understand the functional consequences of our new discoveries as well as 198 
previously reported variants, we carry out a series of in silico investigations including 199 
expression Quantitative Trait Locus (eQTL) analyses, tissue and DNASE hypersensitivity site 200 
enrichment and pathway analyses (Supplementary Fig. 1).  We also test for long-range 201 
regulatory interactions (Hi-C) and investigate metabolomics signatures associated with our 202 
sentinel SNVs. Finally, we undertake experimental analysis of gene expression in relevant 203 
vascular tissue for selected putative functional SNVs.  204 
RESULTS 205 
Discovery and validation of genetic variants at novel loci 206 
Of the 240 not previously reported loci taken forward to replication, we validate 107 novel 207 
loci at P < 5x10-8, of which 102 derive from the GWAS analysis replicated and meta-analysed 208 
in a total of 330,956 individuals (Table 1a; Supplementary Fig. 2a-c; Supplementary Fig. 3a), 209 
and a further five are from the exome analysis validated in a total of 422,604 individuals from 210 
the combined meta-analysis (Table 1b and Supplementary Fig. 3b; Supplementary Tables 5 211 
and 6). Most SNVs also show association with hypertension in the UK Biobank data, for 212 
example 93 of the 107 validated novel sentinel SNVs are nominally significant (P < 0.01) 213 
(Supplementary Table 7). 214 
 215 
Our results for systolic, diastolic and pulse pressure are shown in Supplementary Figs. 2a,b,c 216 
respectively. The most significant association signal for systolic pressure, which rises with age 217 
is with rs112184198 near PAX2 (P =3.6 x 10-18); for diastolic pressure, which plateaus in middle 218 
age, with rs76326501 near METTL21A- ACO16735.1 (P =3.6 x 10-18); and rs3889199 near FGGY 219 
(P = 1.8 X 10-24) for pulse pressure, which increases with age and arterial stiffening18. However, 220 
as blood pressure traits are highly correlated, we unsurprisingly report considerable overlap 221 
in these findings (Supplementary Fig. 4). Many loci are associated with more than one blood 222 
pressure trait at genome-wide significance. For example, in the combined meta-analysis, 24 223 
validated novel loci are associated with both systolic and diastolic pressure, 11 with both 224 
systolic and pulse pressure, one locus with both diastolic and pulse pressure and four loci 225 
(NADK-CPSF3L, GTF2B, METTL21A-AC079767.3 and PAX2) are associated with all three traits 226 
(Fig. 2). We further note that many of the pulse pressure associated SNVs have opposing 227 
directions of effect for systolic and diastolic pressure, and are less likely to have strong 228 
associations with hypertension. 229 
 230 
After conditional analysis on the sentinel SNV we identify five validated secondary SNVs in 231 
novel regions that are independently associated with blood pressure traits (Table 2a; 232 
Supplementary Table 8). We also note the existence of a rare validated potential secondary 233 
variant at the NOX4 locus (rs56061986, MAF = 0.3%); although we do not claim this as an 234 
independent signal after conditioning on the sentinel variant, its relatively large effect on 235 
blood pressure remains (Supplementary Table 8). The contribution of our validated novel loci 236 
increases the percentage trait variance explained by ~1%, e.g. compared with 2.59% for 237 
previously reported SNVs alone, taken together, the validated novel and previously reported 238 
SNVs explain 3.56% of variance for systolic blood pressure, in an independent population. 239 
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 240 
For the first time in GWAS we report a signal at the angiotensin converting enzyme (ACE) locus 241 
(P = 6.8 x 10-14), from the renin-angiotensin system, a pathway which is targeted by current 242 
blood pressure treatments (ACE-inhibitors), as well as several other signals at known 243 
hypertension drug targets. These include CACNA2D2 (rs743757, P = 2.4 x 10-10) targeted by 244 
calcium channel blockers, MME (rs143112823 in the RP11-439C8.2 locus, P = 1.4 x 10-14) 245 
targeted by omapatrilat for treating hypertension, ADRA2B (rs2579519 in the GPAT2-246 
FAHD2CP locus, P = 4.8 x 10-12) targeted by beta blockers, SLC14A2 (rs7236548, P = 2.0 x 10-247 
18) targeted by the hypertension drug nifedipine, and phosphodiesterase 5A (PDE5A; 248 
rs66887589, P = 3.4 x 10-15) targeted by sildenafil for treating pulmonary hypertension.  249 
 250 
Additionally, we evaluate our validated novel SNVs, where available, in cohorts of non-251 
European ancestry12,13, while recognising that these analyses are likely underpowered 252 
(Supplementary Table 9). For the GWAS SNVs, we find concordance in direction of effect (P 253 
<0.05) for all three blood pressure traits for individuals of East Asian ancestry, and for diastolic 254 
pressure for South Asian ancestry. For the exome analyses, we find concordance in direction 255 
of effect among individuals of Hispanic ancestry. Despite small numbers, these findings point 256 
to cosmopolitan effects for many of the blood pressure associated variants.  257 
 258 
A PhenoScanner19 search revealed that 27 of our 107 validated novel sentinel SNVs (or 259 
proxies; r2 ≥ 0.8) exhibit genome-wide significant associations (Fig. 3a) with other traits, 260 
including cardiovascular outcomes (e.g. coronary artery disease, myocardial infarction), 261 
cardiovascular risk factors (e.g. lipids, height, body mass index) and non-cardiovascular traits 262 
(e.g. lung function, cancer, Alzheimer’s). Some of these associations may reflect genuine 263 
pleiotropic effects of variants. In some cases, such as for coronary artery disease, association 264 
with blood pressure may either be due to pleiotropy, or reflect the fact that elevated blood 265 
pressure lies on the causal pathway20.  266 
Associations at previously reported loci 267 
In the conditional analyses, we identify 22 secondary SNVs (17 common, one rare and four 268 
low-frequency variants) that are conditionally independent of the blood pressure associated 269 
SNVs at 16 previously reported loci (Table 2b; Supplementary Tables 10 and 11). One rare 270 
variant (rs138582164, MAF=0.1%) in the CDH17 locus anticipated to act as an exonic 271 
stop/gain mutation at the GEM gene is associated with a relatively large effect on pulse 272 
pressure (3.5 mm Hg per allele copy, Table 2b). At three previously reported loci (EBF1, 273 
PDE3A, JAG1) we identify multiple independent secondary SNVs in addition to the previously 274 
reported SNVs (Supplementary Table 10).  275 
 276 
The UK Biobank data show support (P < 0.01) for 119 of the 122 previously reported blood 277 
pressure loci (159 of 163 SNVs) for one or more blood pressure traits (Supplementary Fig. 2 278 
a-c; Supplementary Table 12). Thus we do not show support in UK Biobank for only four 279 
previously reported SNVs, one of which (rs11066280, RPL6-ALDH1) was identified from a 280 
GWAS of East Asian ancestry21 and may indicate ancestry-specific effects. We compare the 281 
MAF and effect sizes in UK Biobank with the published results of previously reported variants 282 
(Supplementary Figure 5), indicating consistency of results between the two sources of data. 283 
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We also examine findings for low-frequency and rare gene mutations previously reported to 284 
be associated with monogenic hypertension disorders22 and included on the UK Biobank gene 285 
array. Even within a large single study, there is still a lack of power for testing the impact of 286 
rare variants and it remains inconclusive as to whether any monogenic mutations also affect 287 
blood pressure levels within the general population. From the look-up results obtained within 288 
the UK Biobank data (Supplementary Table 13), there is suggestion that the variant with the 289 
lowest P-value (rs387907156; KLH3; MAF=0.02%) has a large effect on blood pressure (8.2 290 
mm Hg per allele (SE=4.1); P = 0.046 and 5.6 mm Hg (SE=2.6); P = 0.048 for systolic and pulse 291 
pressure respectively). 292 
 293 
Functional analyses  294 
We annotate the 107 validated novel loci to 212 genes (based on LD r2 ≥0.8) and seek putative 295 
function from in silico analyses of our novel and previously reported loci, as well as 296 
undertaking gene expression experiments for selected SNVs in relevant vascular tissue. 297 
Candidate genes with the strongest supporting evidence are indicated in the last column of 298 
Table 1 with an indication of the supporting data source. All genome wide-significant variants 299 
in LD (r2>0.8) for (a) validated novel loci and (b) previously reported loci, ranked by supporting 300 
evidence are annotated in Supplementary Table 14. Of the 107 validated novel sentinel SNVs 301 
only three are Indels, all other variants are single nucleotide polymorphisms (SNPs). We 302 
identify non-synonymous SNVs at 13 of the 107 validated novel loci, including three non-303 
synonymous novel sentinel SNVs (rs1250259 at FN1 locus, rs78648104 at TFAP2D and 304 
rs7127805 at CRACR2B locus) (Supplementary Table 15). Furthermore three of the 13 305 
validated novel loci contain non-synonymous SNVs that are predicted to be damaging 306 
(ANNOVAR) in TFAP2D (rs78648104), NOX4 (rs56061986, see above) and CCDC141 307 
(rs17362588, reported to be associated with heart rate23) (Fig. 3a). Beyond the coding regions 308 
we identify 29 novel associated SNVs in 3’UTRs which are predicted to significantly weaken 309 
or cause loss of miRNA regulation by altering the recognition motif in seven genes, and 310 
strengthen or create target sites for miRNA binding in 13 genes (based on miRNASNP db, 311 
Supplementary Table 15). 312 
Our expression Quantitative Trait locus (eQTL) analysis (based on GTEx data) shows that many 313 
novel loci contain variants with eQTLs across a range of different tissues (Supplementary 314 
Table 16). Of the 107 validated novel loci, 59 contain variants with eQTLs in at least one tissue. 315 
We observe arterial tissue as the tissue having the largest number of loci with eQTLs 316 
(Supplementary Fig. 6). Our follow-up targeted in-silico analysis reveals six novel loci with 317 
eQTLs in arterial tissue (Supplementary Table 15). For example, the GTEx tibial artery eQTL 318 
in SF3A3 (rs4360494) shows strong in silico supporting evidence, including an arterial DNase 319 
I site within which the major C allele removes a predicted AP-2 binding site (Supplementary 320 
Fig. 7). Hence we prioritised this gene for in vitro functional analysis (see below).  321 
By considering all loci together from both validated novel and previously reported loci, our 322 
analysis using DEPICT identifies enrichment of expression across 31 tissues and cells 323 
(Supplementary Fig.8; Supplementary Table 17), with greatest enrichment in the arteries (P 324 
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= 1.9 x 10-6, false discovery rate (FDR) < 1%). We use FORGE to investigate and identify 325 
significant (FDR, P <0.05) cell type specific enrichment within DNase I hypersensitive sites in 326 
a range of tissues including dermal and lung microvascular endothelial cell types, and cardiac 327 
fibroblasts (Supplementary Fig. 9). For a set of curated candidate regulatory SNVs from 328 
validated novel loci (see Supplementary Methods), widespread enrichment is found in 329 
microvascular endothelium, aortic smooth muscle, aortic fibroblasts, vascular epithelium, 330 
heart and skin (Supplementary Fig. 9). In addition, we identify significant enrichment of 331 
histone marks in a wide range of cell types, including strong enrichment seen for H3K4Me3 332 
(an activating modification found near promoters) marks in umbilical vein endothelial cells 333 
(HUVEC) (Supplementary Fig. 10). To explore expression at the level of cardiovascular cell 334 
types specifically, we use Fantom5 reference transcript expression data (see Methods Online) 335 
to cluster the 212 genes annotated to our 107 validated novel loci according to tissue 336 
specificity (Supplementary Fig. 11), with the significantly clustered genes forming four tissue-337 
specific clusters, including a vascular smooth muscle cell (VSMC) and fibroblast cluster, an 338 
endothelial cell cluster (including probable endothelial cells in highly vascularised tissues), 339 
and a combined vascular cell cluster.    340 
Additionally, Ingenuity pathway analysis and upstream transcriptional analysis show 341 
enrichment of canonical pathways implicated in cardiovascular disease, including those 342 
targeted by antihypertensive drugs, such as the alpha-adrenergic, CXCR4, endothelin 343 
signalling and angiotensin receptor pathways (Supplementary Table 18). In keeping with 344 
vascular mediation of genetic influence we identify diphenyleneiodonium, an inhibitor of 345 
flavin-containing oxidases, including NAD(P)H oxidase, which is reported to reverse 346 
endothelial dysfunction (and hypertension) in a rat model24.  347 
In order to identify long range target genes of non-coding variants, we use chromatin 348 
interaction (Hi-C) data from HUVEC, as enhancers and silencers often form chromatin loops 349 
with their target promoter. In most loci the strongest promoter interaction involves a gene in 350 
high LD with the SNV but for 21 loci we find a distal potential target gene (Supplementary 351 
Table 15). Ingenuity pathway analysis of the distal genes shows the greatest enrichment in 352 
regulators of cardiac hypertrophy. 353 
We further evaluate pleiotropy using the Genomic Regions Enrichment of Annotations Tool 354 
(GREAT) to study enrichment of mouse phenotype and human disease ontology terms across 355 
all our validated novel and previously reported loci. These highlight cardiovascular system 356 
abnormalities and vascular disease as the most highly enriched terms (Fig. 3b & 3c).  357 
Collectively evidence from eQTLs, DEPICT, DNase I sites, histone marks, Hi-C data and 358 
ontological analyses indicates predominant vascular and cardiovascular tissue involvement 359 
for genes within the blood pressure associated loci. For example, aggregating all loci together 360 
in the DEPICT analysis, we observe greatest enrichment in arterial tissue, which has the largest 361 
proportion of novel loci having variants with eQTLs. 362 
We also look for association of our validated sentinel SNVs with metabolomic signatures. 363 
Three novel SNVs within the NOX4, KCNH4 and LHFPL2 loci show significant associations 364 
(family-wise error rate < 5%) with lipoprotein sub-fractions from 1H Nuclear Magnetic 365 
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Resonance (NMR) spectroscopy analysis of 2,000 Airwave study samples (Supplementary 366 
Tables 19 and 20). The results for these variants suggest a link between blood pressure 367 
regulation and lipid metabolism. Eleven SNVs (including at LHFPL2 locus) show association 368 
(family wise error rate < 5%) with metabolites in blood or urine from the publicly available 369 
“Metabolomics GWAS Server” resource based on mass spectrometry25,26 (Supplementary 370 
Table 20), including sugar acids, sphingolipids, fatty acids, glycerophospholipids, organic acids 371 
and benzene derivatives.   372 
Several genes and variants with putative function are highlighted in our in silico analysis as 373 
having biological support (e.g. eQTLs or nsSNVs) and those with novelty and tractability to 374 
laboratory investigation (e.g. expression in available tissue models) are prioritized. Sentinel 375 
variants in three genes are selected for experimental testing and successfully genotyped, each 376 
for at least 100 samples. We select ADAMTS7 due to strong biological support (e.g. mouse 377 
knockout phenotype), SF3A3 due to eQTLs and NOX4 as it contains a rare nsSNV in addition 378 
to common variant associations. All three SNVs reached highly significant levels of association 379 
with blood pressure in the combined meta-analysis (Table 1): rs62012628 at ADAMTS7 for 380 
diastolic pressure (0.238 mmHg per allele ±0.03, P=5.1x10-12, N=244,143); rs4360494 at SF3A3 381 
for pulse pressure (0.278 mmHg ±0.03, P=3.7x10-16, N=307,682); rs2289125 at NOX4 for pulse 382 
pressure (-0.377 mmHg ±0.04, P=9.1x10-22, N=282,851). We use quantitative polymerase 383 
chain reaction (qPCR) to study the impact of these sentinel variants on gene expression in 384 
human vascular smooth muscle (VSMCs) and endothelial cells (ECs) (see Methods Online). For 385 
SF3A3, the major C allele of sentinel variant rs4360494 associated with increased pulse 386 
pressure is also associated with SF3A3 expression in human VSMCs, although this SNV is not 387 
related to expression in endothelial cells (Supplementary Fig. 12a); and the T allele of SNV 388 
rs62012628 in ADAMTS7, associated with lower diastolic pressure, is associated with reduced 389 
ADAMTS7 expression in human VSMCs (Supplementary Fig. 12b). Moreover, we find that the 390 
minor A allele of sentinel SNV rs2289125 at the NOX4 locus correlates with increased NOX4 391 
expression in ECs though not VSMCs (Supplementary Fig. 12c). Our study thus finds evidence 392 
for novel cis-eQTLs in ADAMTS7 and NOX4 in addition to validating the previously reported 393 
GTEx eQTL in SF3A3, and supports the vascular expression of these genes.   394 
Genetic risk of increased blood pressure, hypertension and cardiovascular outcomes 395 
We create an unbiased genetic risk score (GRS) (Supplementary Table 21) to evaluate, in an 396 
independent cohort (Airwave, see Methods Online), the impact of the combination of our 397 
validated novel and previously reported loci on blood pressure levels and risk of hypertension. 398 
When compared with the lowest quintile of the distribution of the GRS, individuals >50 years 399 
in the highest quintile have sex-adjusted mean systolic pressure higher by 9.3 mm Hg (95% CI 400 
6.9 to 11.7 mm Hg, P =1.0 x 10-13) and an over two-fold higher risk of hypertension (OR 2.32 401 
95% CI 1.76 to 3.06; P=2.8 x 10-9) compared with individuals in the lowest quintile of the GRS 402 
distribution (Fig. 4; Supplementary Table 22). Similar results were obtained from GRS 403 
associations with blood pressure and hypertension within UK Biobank (Supplementary Table 404 
23). In UK Biobank − based on self-reported health data, record linkage to Hospital Episode 405 
Statistics and mortality follow-up data (Supplementary Table 24) − we show that the GRS is 406 
associated with increased risk of stroke, coronary heart disease and all cardiovascular 407 
outcomes, comparing the upper and lower fifths of the GRS distribution, with sex-adjusted 408 
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odds ratios of 1.34 (95% CI 1.20 to 1.49, P =1.5×10-7), 1.38 (95% CI 1.30 to 1.47, P= 4.3×10-23) 409 
and 1.35 (95% CI 1.27 to 1.42, P=1.3×10-25) respectively (Fig. 4; Supplementary Table 25). 410 
Results are also provided for incident-only cases (Supplementary Table 26). 411 
 412 
DISCUSSION  413 
A key attribute of this study is the combination of a large, single discovery sample with 414 
standardized blood pressure measurement and a dense 1000 Genomes imputation strategy 415 
(UK 10K enhanced 1000G imputation), yielding a high quality dataset of ~9.8 million variants 416 
for study16. This is the largest genetic association analysis for blood pressure to date taking 417 
advantage of major international consortia for parallel replication of common and low-418 
frequency variants, based in total on data from 330,956 individuals and exonic SNVs in a total 419 
of 422,604 individuals27. This strategy resulted in the discovery of 107 robustly validated novel 420 
loci for blood pressure traits. In previous large-scale blood pressure genome-wide association 421 
scans we estimated that an effective doubling of sample size from a discovery cohort of 422 
70,000 to 140,000 individuals with ~2.5 million imputed variants would double the number 423 
of validated loci, resulting in an estimated ~30 additional loci for blood pressure traits27. Here 424 
we find over three times that number, taking advantage of UK Biobank’s standardized 425 
approach to data collection, biobanking, genotyping and enhanced imputation strategy. 426 
Despite its size, our study is still under-powered to find low-frequency variants and the vast 427 
majority of our findings are common variants, with similarly modest or small effect sizes as 428 
previously reported validated variants (Supplementary Fig. 13). Our GWAS, which was 429 
restricted to MAF ≥ 1%, only identified four novel sentinel SNVs of low-frequency (1% ≤ MAF 430 
< 5%) and our Exome analysis, despite allowing for rare variant discovery, did not identify any 431 
rare novel sentinel SNVs. The only rare and low-frequency variants identified were secondary 432 
SNVs within previously reported loci. The lack of rare variant discovery could also be due to 433 
the challenge of detecting rare variants from imputed data, in contrast to the recent Exome-434 
chip studies which identified some novel rare SNVs from genotyped data11,12. There may be 435 
greater potential for identifying rare variants from the future release of genetic data for all 436 
500,000 UK Biobank participants.  437 
Our findings point to new biology as well as highlighting novel gene regions in systems that 438 
have previously been implicated in the genetics of blood pressure. Several of our validated 439 
novel loci affect atherosclerosis or vascular remodelling (ADAMTS7, THBS2, CFDP1) and 440 
exhibit locus pleiotropy in prior genome-wide association studies for coronary artery disease 441 
or carotid intimal-media thickness28-30 (Fig. 3a  and Fig. 5). In previous work we have shown 442 
that expression of ADAMTS7 is upregulated and increases vascular smooth muscle cell 443 
migration in response to vascular injury in relation to a distinct coronary artery variant 444 
(rs3825807 which is not in strong LD with our sentinel SNV; r2 = 0.17)31. In endothelial cells 445 
ADAMTS7 acts as a metalloproteinase to cleave thrombospondin-1 encoded by THBS2 which 446 
leads to reduced endothelial cell migration and plays a role in neo-intimal repair in the vessel 447 
wall31. Our functional work indicates that the allele associated with lower diastolic pressure 448 
is also associated with lower ADAMTS7 expression in human vascular smooth muscle cells; 449 
this fits with the murine knockout that exhibits reduced atherosclerosis. SF3A3 is a splicing 450 
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factor with no prior links to blood pressure other than our reported association and eQTL. 451 
NOX4 has an established role in the endothelium where it enhances vasodilatation and 452 
reduces blood pressure in vivo32. At the CFDP1 locus our sentinel SNV is in high LD (r2 = 0.95) 453 
with a variant previously associated with carotid intimal-medial thickness. Collectively our 454 
findings highlight a potential common mechanism among these genes in vascular remodelling 455 
that has previously been observed in small resistance arteries in essential hypertension33.  456 
We identify both common and rare variant associations at the novel NADPH oxidase 4 (NOX4) 457 
locus. This oxidase generates reactive oxygen species in the endothelium and may contribute 458 
to salt sensitive hypertension in the kidney and the vasculature34-36. We found that the allele 459 
of the common variant at NOX4 locus correlates with increased tissue specific NOX4 460 
expression in endothelial cells rather than vascular smooth muscle cells (Supplementary 461 
Figure 12c). NOX4 mediates endothelial cell apoptosis and facilitates vascular collagen 462 
synthesis contributing to endothelial dysfunction and arterial stiffness, and may explain the 463 
association with pulse pressure37,38.  464 
We identify several loci containing genes involved in vascular signalling and second 465 
messenger systems such as PDE5A and PDE10A39-41. The phosphodiesterase PDE5A 466 
hydrolyses cyclic GMP and is inhibited by sildenafil which leads to vasodilatation42. This 467 
finding fits with our previous discoveries of a role for gene loci encoding elements of 468 
natriuretic peptide-nitric oxide pathway and guanylate cyclase signalling systems in blood 469 
pressure regulation21,43,44.  Our findings strengthen the case for evaluating the opportunity to 470 
repurpose PDE5A inhibitors for use in hypertension. 471 
The importance of microvascular function is emphasised by the solute carrier transporters 472 
such as SLC14A2 encoding a urea transporter, which has previously been linked to autosomal 473 
dominant Streeten type orthostatic hypotensive disorder45 and blood pressure response to 474 
nifedipine, a calcium channel blocker antihypertensive drug46.  SLC8A1 encodes a sodium 475 
calcium exchanger expressed in cardiomyocytes which alters cardiac contractility and 476 
hypertrophy and shows abnormal blood pressure in SLC8A1 transgenic mice47. Variants at 477 
SLC35F1 have been previously associated with resting heart rate and ventricular dimensions 478 
which could contribute to blood pressure elevation48.  479 
We also identify loci that are involved in cardiovascular development (GATA2, KIAA1462, 480 
FBN2, FN1 and HAND2) such as fibrillin 2 (FBN2) which overlaps in action with fibrillin 1 in 481 
development of the aortic matrix49-53. In addition, fibronectin expression is increased in 482 
hypertension and in atherosclerosis but it may also play a role in the development of the 483 
heart53-55. 484 
Our analysis validates loci containing genes with prior physiological connection to blood 485 
pressure such as BDNF, FAM208A, and CACNA2D256-58. The neurotrophin Brain Derived 486 
Neurotrophic Factor modulates angiotensin 11 in the brain to elevate blood pressure in 487 
experimental models and higher serum levels correlate with reduced risk of cardiovascular 488 
disease and mortality56. In experimental models FAM208A, which is thought to be a 489 
transcription factor, is a strong candidate for a quantitative trait locus for blood pressure58. 490 
The gene CACNA2D2 encodes a subunit of the L-type calcium channel that is most abundantly 491 
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expressed in the atrium and in neurones and may be a target for negatively chronotropic and 492 
inotropic calcium channel antagonists which reduce blood pressure59.  493 
This is the first time long range genomic interactions have been sought using Hi-C for blood 494 
pressure, where the promoter region has a strong chromatin interaction with a novel SNV. 495 
One such gene is EPAS1, which is ~200kb away from the SNV (rs11690961). It encodes 496 
hypoxia-inducible factor 2alpha, which affects catecholamine homeostasis, protects against 497 
heart failure and mutations in the gene are associated with pulmonary hypertension60. 498 
Another gene is INHBA, 1.3Mb away from the SNV (rs12531683), which is elevated in 499 
pulmonary hypertension and contributes to vascular remodelling by inducing expression of 500 
endothelin-1 and plasminogen activator inhibitor-1 in pulmonary smooth muscle cells61. 501 
Our observation that the blood pressure genetic risk score is associated with 9-10 mm Hg 502 
higher blood pressure at age 50+ years when comparing the top vs bottom fifths of the 503 
distribution in an independent population has potential clinical and public health implications. 504 
The results are particularly striking when stratified by age, due to a significant interaction of 505 
the GRS with age (P ranging between 9.96×10-11 and 1.16×10-3 for interaction with continuous 506 
blood pressure traits, and P = 0.012 for hypertension). Measuring the genetic risk score in 507 
early life raises the possibility of adopting an early precision medicine approach to risk 508 
management through lifestyle intervention (i.e. reduced sodium intake, increased potassium 509 
intake, maintenance of optimal weight, low adult alcohol consumption and regular 510 
exercise)62-64. Indeed, studies of non-pharmacologic approaches to blood pressure control 511 
indicate that we might achieve 10 mm Hg or more reduction in systolic blood pressure 512 
through lifestyle measures alone65. At the same time, recent evidence suggests that favorable 513 
lifestyle may offset the cardiovascular sequelae associated with high genetic risk66. However, 514 
as the above data are observational, it is not certain to what extent adherence to lifestyle 515 
recommendations amongst high genetic risk individuals could result in favorable outcomes. 516 
Given the substantial effect of genetic risk score on blood pressure by middle-age, the 517 
potential for adopting early lifestyle intervention amongst individuals at high genetic risk, 518 
along with population-wide measures to lower blood pressure, warrants further study. 519 
Since the completion of our study, another blood pressure GWAS has been recently 520 
published67. This used UK Biobank data within a larger single-stage combined meta-analysis, 521 
reporting a total of 316 loci, including 241 loci identified from the meta-analysis involving UK 522 
Biobank that were not tested for validation, as no replication resource was available. Our 523 
study reports 107 validated novel loci, of which 32 are detected and validated for the first 524 
time in our analysis of UK Biobank. In addition, 75 sentinel SNVs are in LD (r2 ≥ 0.2) with the 525 
recently reported loci and we are able to validate at least 53 of these for the first time in our 526 
study. Furthermore we note that 49 of the reported loci from this recent study67 did not 527 
validate in our large independent replication resource. 528 
We describe 107 validated novel loci for blood pressure offering new biology, identifying 529 
potential new therapeutic targets and raising the possibility of a precision medicine approach 530 
to modify risk of hypertension and cardiovascular outcomes.  In total this brings the number 531 
of combined validated novel and previously reported loci for blood pressure traits to 229, 532 
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representing a major advance in our understanding of the genetic architecture of blood 533 
pressure.  534 
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Table 1: Association results for the sentinel variant from each validated novel locus from (a) UK Biobank GWAS discovery and (b) UK 765 
Biobank exome discovery. Results are shown for the primary blood pressure trait with most significant association from the combined meta-766 
analysis.  767 
(a) UK Biobank GWAS      
Sentinel SNV in the locus  UK Biobank discovery Replication Combined   
Locus Chr Pos rsID EA EAF Beta SE P Beta SE P N Beta SE P Traits Candidate genes 
Systolic blood pressure      
NADK-CPSF3L 1 1,685,921 rs139385870 D 0.50 -0.394 0.07 1.9x10
-8 -0.310 0.07 1.0x10-5 281,890 -0.352 0.05 1.3x10-12 DBP,PP GNB1df, NADKefg 
CELA2A 1 
15,798,197 
rs3820068 A 0.81 0.497 0.09 2.4x10-8 0.367 0.08 5.3x10-6 310,776 0.425 0.06 1.1x10-12 PP AGMATdf, 
CELA2Aefg 
GTF2B 1 89,360,158 rs10922502 A 0.62 -0.475 0.07 4.7x10
-11 -0.307 0.06 2.0x10-6 323,666 -0.382 0.05 2.2x10-15 DBP,PP KYAT3bf, GTF2Bdefg 
FOSL2 2 28,635,740 rs7562 T 0.52 0.365 0.07 2.2x10-7 0.182 0.06 3.7x10-3 319,942 0.263 0.05 1.9x10-8  FOSL2efg 
PRKD3 2 37,517,566 rs13420463 A 0.77 0.504 0.08 1.4x10
-9 0.244 0.07 7.3x10-4 330,307 0.356 0.05 7.0x10-11 DBP PRKD3efg 
METTL21A-AC079767.3 2 208,526,140 rs55780018 T 0.54 -0.426 0.07 1.7x10-9 -0.360 0.07 5.1x10-8 304,567 -0.391 0.05 5.9x10-16 DBP,PP METTL21Aefg 
RYK 3 134,000,025 rs9859176 T 0.40 0.419 0.07 6.4x10-9 0.248 0.06 9.6x10-5 322,428 0.322 0.05 1.3x10-11 DBP RYKefg 
NPNT 4 106,911,742 rs13112725 C 0.76 0.418 0.08 3.1x10
-7 0.450 0.08 9.4x10-9 306,370 0.435 0.06 1.5x10-14 DBP NPNTdfg 
TMEM161B 5 87,514,515 rs10059921 T 0.08 -0.644 0.13 5.9x10-7 -0.417 0.12 7.9x10-4 298,543 -0.526 0.09 4.0x10-9  TMEM161Bg 
FBN2 5 127,868,199 rs6595838 A 0.30 0.483 0.08 2.0x10
-10 0.236 0.07 4.5x10-4 328,401 0.344 0.05 7.6x10-12 DBP FBN2defg 
CASC15 6 22,130,601 rs6911827 T 0.45 0.433 0.07 8.2x10-10 0.190 0.06 2.1x10-3 326,471 0.296 0.05 2.0x10-10 DBP CASC15efg 
TFAP2D 6 50,683,009 rs78648104 T 0.92 -0.664 0.13 1.2x10-7 -0.329 0.11 4.0x10-3 305,426 -0.481 0.08 1.3x10-8 DBP TFAP2Daefg 
MKLN1 7 131,059,056 rs13238550 A 0.40 0.486 0.07 9.4x10
-12 0.212 0.06 7.1x10-4 325,647 0.331 0.05 1.9x10-12 DBP PODXLcf, MKLN1efg 
HIPK2 7 
139,463,264 
rs1011018 A 0.20 -0.441 0.09 6.1x10-7 -0.244 0.08 1.6x10-3 325,110 -0.329 0.06 1.5x10-8  TBXAS1cdf, 
HIPK2cdefg 
ZFAT 8 135,612,745 rs894344 A 0.60 -0.384 0.07 6.8x10
-8 -0.163 0.06 8.2x10-3 329,834 -0.258 0.05 3.2x10-8  ZFATdfg 
PAX2 10 102,604,514 rs112184198 A 0.10 -0.826 0.12 7.8x10-13 -0.532 0.10 1.3x10-7 323,791 -0.659 0.08 3.6x10-18 DBP,PP PAX2cefg 
MCF2L 13 113,636,156 rs9549328 T 0.23 0.440 0.08 1.5x10
-7 0.218 0.08 3.9x10-3 313,787 0.318 0.06 1.5x10-8 PP MCF2Ldefg 
FERMT2 14 53,377,540 rs9888615 T 0.29 -0.427 0.08 3.5x10-8 -0.236 0.07 4.3x10-4 326,235 -0.318 0.05 3.5x10-10  FERMT2defg 
PPP2R5E 14 63,928,546 rs8016306 A 0.80 0.454 0.09 2.5x10
-7 0.250 0.07 7.9x10-4 329,869 0.335 0.06 3.7x10-9 DBP PPP2R5Eefg 
ABHD17C 15 81,013,037 rs35199222 A 0.45 0.353 0.07 5.7x10
-7 0.298 0.06 1.7x10-6 323,407 0.322 0.05 5.2x10-12 DBP ABHD17Cefg 
CFDP1 16 
75,331,044 
rs11643209 T 0.42 -0.481 0.07 1.8x10-11 -0.222 0.06 6.3x10-4 309,242 -0.339 0.05 1.8x10-12 PP CFDP1bfg, 
BCAR1def 
CRK 17 1,333,598 rs12941318 T 0.49 -0.317 0.07 6.2x10
-6 -0.226 0.07 6.9x10-4 299,739 -0.269 0.05 2.5x10-8 PP CRKcdfg 
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ACOX1 17 73,949,045 rs2467099 T 0.22 -0.423 0.08 4.5x10
-7 -0.216 0.07 3.6x10-3 326,401 -0.307 0.06 3.3x10-8  ACOX1dfg, FBF1acef 
Diastolic blood pressure      
chr1mb25 1 25,030,470 rs6686889 T 0.25 0.231 0.05 3.7x10-7 0.143 0.04 9.1x10-4 322,575 0.185 0.03 3.6x10-9  RUNX3df, 
CLIC4cdef, SRRM1g 
DNM3 1 172,357,441 rs12405515 T 0.56 -0.219 0.04 4.1x10-8 -0.118 0.04 1.6x10-3 328,543 -0.165 0.03 1.4x10-9  DNM3defg 
GPATCH2 1 217,718,789 rs12408022 T 0.26 0.226 0.05 5.9x10-7 0.172 0.04 6.7x10-5 320,983 0.198 0.03 2.4x10-10  GPATCH2g 
CDC42BPA 1 227,252,626 rs10916082 A 0.73 -0.222 0.04 5.3x10-7 -0.135 0.04 1.5x10-3 327,636 -0.177 0.03 8.4x10-9  CDC42BPAefg 
WNT3A 1 228,191,075 rs2760061 A 0.47 0.235 0.04 3.7x10-9 0.225 0.04 1.1x10-8 312,761 0.230 0.03 2.1x10-16 SBP WNT9Adf, 
WNT3Aefg 
SDCCAG8 1 243,471,192 rs953492 A 0.46 0.293 0.04 1.2x10-13 0.153 0.04 4.6x10-5 325,253 0.220 0.03 7.4x10-16  SDCCAG8bcefg 
ADCY3 2 25,139,596 rs55701159 T 0.89 0.382 0.06 1.1x10-9 0.193 0.06 1.6x10-3 321,052 0.285 0.04 7.2x10-11 SBP ADCY3efg 
SLC8A1 2 40,567,743 rs4952611 T 0.58 -0.200 0.04 8.0x10-7 -0.114 0.04 4.6x10-3 309,395 -0.157 0.03 4.0x10-8  SLC8A1cdefg 
AC016735.1 2 43,167,878 rs76326501 A 0.91 0.426 0.07 4.3x10-10 0.413 0.07 1.5x10-9 318,127 0.419 0.05 3.6x10-18 SBP PRKCEdf, HAAOg 
GPAT2-FAHD2CP 2 96,675,166 rs2579519 T 0.63 -0.259 0.04 1.7x10-10 -0.137 0.04 6.7x10-4 311,557 -0.197 0.03 4.8x10-12  ADRA2Bcdf, 
TCF7L1cef, 
FAHD2CPefg 
TEX41 2 145,646,072 rs1438896 T 0.30 0.288 0.04 2.1x10-11 0.187 0.04 4.3x10-6 329,278 0.234 0.03 2.0x10-15 SBP TEX41g 
CCDC141 2 179,786,068 rs79146658 T 0.91 -0.375 0.07 5.8x10-8 -0.245 0.07 4.2x10-4 321,318 -0.311 0.05 2.4x10-10  CCDC141afg 
TMEM194B 2 191,439,591 rs7592578 T 0.19 -0.271 0.05 8.9x10-8 -0.212 0.05 1.7x10-5 304,672 -0.240 0.04 9.5x10-12 SBP NAB1g 
TNS1 2 218,668,732 rs1063281 T 0.60 -0.231 0.04 1.2x10-8 -0.172 0.04 1.4x10-5 315,354 -0.200 0.03 1.3x10-12 SBP TNS1cefg 
CAMKV-ACTBP13 3 49,913,705 rs36022378 T 0.80 -0.265 0.05 6.3x10-8 -0.140 0.05 3.9x10-3 319,983 -0.202 0.03 4.7x10-9  CAMKVefg 
CACNA2D2 3 50,476,378 rs743757 C 0.14 0.313 0.06 2.9x10-8 0.184 0.05 5.1x10-4 328,836 0.245 0.04 2.4x10-10  CACNA2D2dfg, 
C3orf18def 
FAM208A 3 56,726,646 rs9827472 T 0.37 -0.207 0.04 3.6x10-7 -0.148 0.04 1.7x10-4 323,058 -0.177 0.03 4.3x10-10  FAM208Aefg 
RP11-439C8.2 3 154,707,967 rs143112823 A 0.09 -0.484 0.07 2.9x10-12 -0.295 0.08 2.3x10-4 297,343 -0.403 0.05 1.4x10-14 SBP MMEdefg 
SENP2 3 185,317,674 rs12374077 C 0.35 0.203 0.04 8.3x10-7 0.127 0.04 1.2x10-3 327,513 0.163 0.03 9.2x10-9  SENP2efg 
PDE5A 4 120,509,279 rs66887589 T 0.52 -0.296 0.04 5.7x10-14 -0.140 0.04 2.1x10-4 324,397 -0.215 0.03 3.4x10-15  FABP2cf, PDE5Adefg 
POC5 5 75,038,431 rs10078021 T 0.63 -0.223 0.04 4.7x10-8 -0.105 0.04 9.2x10-3 314,172 -0.164 0.03 1.3x10-8  POC5efg 
CPEB4 5 173,377,636 rs72812846 A 0.28 -0.232 0.04 1.6x10-7 -0.186 0.04 2.4x10-5 312,601 -0.209 0.03 2.2x10-11  C5orf47ef, CPEB4g 
PKHD1 6 51,832,494 rs13205180 T 0.49 0.218 0.04 3.7x10-8 0.123 0.04 1.1x10-3 325,419 0.168 0.03 7.0x10-10  PKHD1cefg 
PDE10A 6 166,178,451 rs147212971 T 0.06 -0.421 0.08 2.3x10-7 -0.289 0.09 9.4x10-4 296,010 -0.360 0.06 1.6x10-9  PDE10Adefg 
SLC35F1 6 118,572,486 rs9372498 A 0.08 0.459 0.07 5.4x10-10 0.231 0.07 5.6x10-4 330,625 0.334 0.05 1.8x10-11 SBP SLC35F1dfg 
SNX31 8 101,676,675 rs2978098 A 0.54 0.212 0.04 6.9x10-8 0.122 0.04 1.4x10-3 324,424 0.165 0.03 1.5x10-9  SNX31efg 
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RP11-273G15.2 8 144,060,955 rs62524579 A 0.53 -0.202 0.04 2.8x10-7 -0.140 0.05 2.2x10-3 268,645 -0.175 0.03 3.8x10-9  CYP11B1cdf, 
CYP11B2cfg 
MTAP 9 21,801,530 rs4364717 A 0.55 -0.218 0.04 3.5x10-8 -0.136 0.04 2.9x10-4 327,173 -0.175 0.03 1.3x10-10  MTAPacefg 
BDNF 11 27,728,102 rs11030119 A 0.31 -0.211 0.04 7.0x10-7 -0.119 0.04 3.3x10-3 330,002 -0.163 0.03 2.9x10-8  BDNFcdefg 
MYEOV 11 69,079,707 rs67330701 T 0.09 -0.415 0.07 7.8x10-9 -0.314 0.08 3.8x10-5 276,760 -0.367 0.05 2.1x10-12 SBP MYEOVefg 
RP11-321F6.1 15 66,869,072 rs7178615 A 0.37 -0.207 0.04 3.8x10-7 -0.152 0.04 1.0x10-4 318,076 -0.179 0.03 2.6x10-10  LCTLefg 
ADAMTS7 15 79,070,000 rs62012628 T 0.29 -0.295 0.04 2.1x10-11 -0.147 0.06 7.7x10-3 244,143 -0.238 0.03 5.1x10-12  ADAMTS7cdefg 
chr15mb95 15 95,312,071 rs12906962 T 0.68 -0.292 0.04 5.3x10-12 -0.155 0.04 1.5x10-4 319,952 -0.221 0.03 5.6x10-14 SBP LOC440311ef, 
MCTP2g 
PPL 16 4,943,019 rs12921187 T 0.43 -0.203 0.04 3.0x10-7 -0.147 0.04 1.2x10-4 326,469 -0.174 0.03 2.5x10-10 SBP PPLaefg 
FBXL19 16 30,936,743 rs72799341 A 0.24 0.235 0.05 3.0x10-7 0.139 0.04 1.6x10-3 324,502 0.185 0.03 5.8x10-9  CTF1cdf, FBXL19efg 
CMIP 16 81,574,197 rs8059962 T 0.42 -0.241 0.04 2.0x10-9 -0.103 0.04 8.5x10-3 319,839 -0.170 0.03 1.3x10-9  CMIPg 
ACE 17 61,559,625 rs4308 A 0.37 0.242 0.04 3.2x10-9 0.186 0.04 2.7x10-6 319,394 0.213 0.03 6.8x10-14 SBP ACEcdefg 
MAPK4 18 48,142,854 rs745821 T 0.76 0.236 0.05 3.2x10-7 0.150 0.04 4.2x10-4 330,954 0.189 0.03 1.4x10-9  MAPK4defg 
CCNE1 19 30,294,991 rs62104477 T 0.33 0.209 0.04 7.1x10-7 0.148 0.04 2.4x10-4 320,347 0.177 0.03 1.2x10-9  CCNE1efg 
PLCB1 20 8,626,271 rs6108168 A 0.25 -0.305 0.05 1.5x10-11 -0.127 0.04 2.9x10-3 327,368 -0.211 0.03 1.1x10-11 SBP PLCB1defg 
Pulse pressure      
chr1mb9 1 9,441,949 rs9662255 A 0.43 -0.303 0.05 4.7x10-10 -0.130 0.04 3.0x10-3 310,618 -0.207 0.03 1.9x10-10  SPSB1efg 
SF3A3 1 38,455,891 rs4360494 C 0.55 0.332 0.05 5.7x10-12 0.224 0.05 3.6x10-6 282,851 0.278 0.03 3.7x10-16  SF3A3bfg, FHL3bef 
RP4-710M16.1-PPAP2B 1 56,576,924 rs112557609 A 0.35 0.280 0.05 3.2x10-8 0.187 0.04 1.8x10-5 325,952 0.227 0.03 6.8x10-12 SBP PLPP3cefg 
FGGY 1 59,653,742 rs3889199 A 0.71 0.462 0.05 3.3x10-18 0.271 0.05 1.9x10-9 329,486 0.351 0.03 1.8x10-24 SBP FGGYdfg, HSD52ef 
C2orf43 2 20,881,840 rs2289081 C 0.36 -0.251 0.05 5.3x10-7 -0.203 0.04 1.7x10-6 329,140 -0.223 0.03 5.5x10-12  GDF7efg 
PRKCE 2 46,363,336 rs11690961 A 0.88 0.437 0.07 4.2x10-9 0.266 0.07 4.6x10-5 327,847 0.340 0.05 3.9x10-12  PRKCEdfg 
CEP68 2 65,283,972 rs74181299 T 0.62 0.296 0.05 2.1x10-9 0.181 0.04 2.0x10-5 324,224 0.230 0.03 9.6x10-13 SBP CEP68efg 
TCF7L1 2 85,491,365 rs11689667 T 0.54 0.256 0.05 1.1x10-7 0.118 0.04 3.8x10-3 330,634 0.176 0.03 1.7x10-8  TCF7L1cefg 
FN1 2 216,300,482 rs1250259 A 0.74 -0.457 0.05 5.5x10-17 -0.210 0.05 7.7x10-6 325,485 -0.314 0.04 8.7x10-19 SBP FN1cedfg 
GATA2 3 128,201,889 rs62270945 T 0.03 0.861 0.14 2.6x10-9 0.366 0.14 9.5x10-3 279,925 0.607 0.10 1.8x10-9  GATA2cefg 
PALLD 4 169,717,148 rs1566497 A 0.42 0.320 0.05 6.6x10-11 0.173 0.04 4.8x10-5 320,948 0.236 0.03 1.9x10-13  PALLDcdfg 
chr4mb174 4 174,584,663 rs17059668 C 0.92 -0.442 0.09 9.0x10-7 -0.245 0.08 2.2x10-3 313,277 -0.332 0.06 2.8x10-8  HAND2-AS1g 
LHFPL2 5 77,837,789 rs10057188 A 0.46 -0.280 0.05 5.5x10-9 -0.149 0.04 3.3x10-4 325,985 -0.205 0.03 6.7x10-11 SBP LHFPL2efg 
GJA1 6 121,781,390 rs11154027 T 0.47 0.311 0.05 1.1x10-10 0.125 0.04 3.7x10-3 316,708 0.207 0.03 1.1x10-10  GJA1cdfg 
ESR1 6 152,397,912 rs36083386 I 0.11 0.651 0.08 4.6x10-17 0.289 0.07 1.0x10-5 323,303 0.439 0.05 1.5x10-18  ESR1ecdfg 
FNDC1 6 159,699,125 rs449789 C 0.14 0.480 0.07 2.2x10-12 0.264 0.06 1.3x10-5 325,584 0.359 0.05 2.4x10-15  FNDC1defg 
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THBS2 6 169,587,103 rs1322639 A 0.78 0.433 0.06 7.7x10-14 0.230 0.05 3.4x10-6 319,866 0.316 0.04 4.8x10-17  THBS2cdefg 
SUGCT 7 40,447,971 rs76206723 A 0.10 -0.405 0.08 2.6x10-7 -0.305 0.07 3.8x10-6 328,162 -0.346 0.05 7.4x10-12  SUGCTg 
SLC20A2 8 42,324,765 rs2978456 T 0.55 -0.253 0.05 1.3x10-7 -0.130 0.05 4.4x10-3 304,964 -0.188 0.03 1.2x10-8  SLC20A2defg 
TRAPPC9 8 141,060,027 rs4454254 A 0.63 -0.320 0.05 9.4x10-11 -0.217 0.04 2.9x10-7 330,022 -0.261 0.03 5.1x10-16  TRAPPC9efg 
SCAI 9 127,900,996 rs72765298 T 0.87 -0.392 0.07 5.9x10-8 -0.358 0.07 8.6x10-8 316,271 -0.374 0.05 2.7x10-14 SBP RABEPKaf, SCAIefg 
KIAA1462 10 30,317,073 rs9337951 A 0.34 0.301 0.05 7.6x10-9 0.262 0.05 5.5x10-8 299,646 0.280 0.04 2.5x10-15  KIAA1462defg 
ARHGAP12 10 32,082,658 rs10826995 T 0.71 -0.317 0.05 2.2x10-9 -0.133 0.05 3.9x10-3 327,373 -0.212 0.03 1.1x10-9  ZEB1cf, 
ARHGAP12efg 
PRDM11 11 45,208,141 rs11442819 I 0.11 -0.412 0.07 3.8x10-8 -0.185 0.06 3.3x10-3 326,483 -0.279 0.05 7.1x10-9  PRDM11efg 
NOX4 11 89,224,453 rs2289125 A 0.21 -0.481 0.06 3.1x10-16 -0.293 0.05 2.9x10-8 307,682 -0.377 0.04 9.1x10-22  NOX4acdefg 
CEP164 11 117,283,676 rs8258 T 0.38 0.341 0.05 5.3x10-12 0.157 0.04 2.4x10-4 327,038 0.236 0.03 2.9x10-13  CEP164defg 
CCDC41 12 94,880,742 rs139236208 A 0.10 -0.442 0.08 5.7x10-8 -0.288 0.08 2.8x10-4 291,244 -0.363 0.06 1.6x10-10  CEP83-AS1ef, 
CEP83g 
RP11-61O1.1 14 98,587,630 rs9323988 T 0.63 -0.291 0.05 5.6x10-9 -0.156 0.04 2.0x10-4 327,551 -0.212 0.03 4.1x10-11  C14orf177g 
VAC14 16 70,755,610 rs117006983 A 0.01 1.448 0.30 9.4x10-7 0.847 0.16 1.8x10-7 250,766 0.986 0.14 4.1x10-12  VAC14efg 
CDH13 16 83,045,790 rs7500448 A 0.75 0.386 0.06 4.2x10-12 0.288 0.05 1.8x10-9 321,958 0.329 0.04 1.1x10-19  CDH13bdefg 
KIAA0753 17 6,473,828 rs7226020 T 0.56 -0.348 0.05 1.3x10-12 -0.175 0.05 1.4x10-4 303,389 -0.256 0.03 2.3x10-14  KIAA0753bfg, 
PITPNM3ef 
TP53-SLC2A4 17 7,571,752 rs78378222 T 0.99 1.530 0.22 8.9x10-12 0.487 0.18 7.9x10-3 294,053 0.904 0.14 1.8x10-10 DBP TP53cdefg 
KCNH4-HSD17B1 17 40,317,241 rs79089478 T 0.97 0.842 0.15 1.2x10-8 0.377 0.13 4.4x10-3 318,326 0.584 0.10 3.1x10-9  KCNH4g 
PYY 17 42,060,631 rs62080325 A 0.66 -0.260 0.05 3.6x10-7 -0.128 0.05 4.8x10-3 315,689 -0.186 0.03 4.0x10-8  PYYcefg 
MRC2 17 60,767,151 rs740698 T 0.56 -0.307 0.05 2.1x10-10 -0.161 0.04 2.8x10-4 311,450 -0.228 0.03 3.1x10-12  MRC2efg 
SLC14A2 18 43,097,750 rs7236548 A 0.18 0.462 0.06 1.1x10-13 0.273 0.05 2.2x10-7 330,075 0.352 0.04 2.0x10-18  SLC14A2cdefg 
SLC24A3 20 19,465,907 rs6081613 A 0.28 0.326 0.05 1.2x10-9 0.213 0.05 8.1x10-6 315,546 0.263 0.04 1.6x10-13  SLC24A3efg 
ARVCF 22 19,967,980 rs12628032 T 0.30 0.269 0.05 2.4x10-7 0.216 0.05 3.8x10-6 310,292 0.240 0.03 5.5x10-12 SBP ARVCFefg 
XRCC6 22 42,038,786 rs73161324 T 0.05 0.611 0.11 6.5x10-9 0.380 0.11 3.1x10-4 267,722 0.496 0.07 2.8x10-11  XRCC6g 
(b) UK Biobank exome  
Systolic blood pressure      
SSPN 12 26,438,189 rs6487543 A 0.77 0.345 0.09 5.9x10-5 0.279 0.06 2.1x10-6 244,842 0.300 0.05 6.3x10-10 DBP SSPNdfg 
Diastolic blood pressure              
MRAS 3 138,119,952 rs2306374 T 0.84 -0.237 0.05 9.3x10-6 -0.155 0.04 9.3x10-5 281,715 -0.184 0.03 7.4x10-9 SBP MRASdefg 
Pulse pressure              
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CD34 1 208,024,820 rs12731740 T 0.10 -0.360 0.08 5.8x10-6 -0.202 0.05 1.1x10-4 279,078 -0.249 0.04 1.1x10-8  MIR29B2df, 
CD34dfg, 
LOC148696ef 
ZNF638 2 71,627,539 rs3771371 T 0.57 -0.223 0.05 4.1x10-6 -0.130 0.03 9.6x10-5 280,285 -0.160 0.03 5.8x10-9  DYSFdf, ZNF638efg 
CRACR2B 11 828,916 rs7126805 A 0.73 0.262 0.05 1.1x10-6 0.184 0.05 4.6x10-4 145,162 0.222 0.04 3.3x10-9  CD151cdfg, 
CRACR2Bef 
 768 
Locus: named according to the nearest annotated gene(s); Pos: build 37; EA: effect allele; EAF: effect allele frequency from discovery data in UK Biobank; Beta: effect 769 
estimate from linear regression; SE: Standard Error of effect estimate; P: P-value of association;  N: total sample size analysed; Traits: the other BP traits which reached 770 
genome-wide significance in the combined meta-analysis. Note: within the UK Biobank discovery analysis sample size was N=140,882/140,886 for systolic and pulse 771 
pressure / diastolic pressure, imputation quality score from SNPTEST ≥ 0.93 for all loci.  772 
Candidate genes have been identified by one or multiple strategies: 773 
acoding, nonsynonymous variant;  774 
bGTEX eQTL  775 
cCV KO Phenotype  776 
dsupporting biology 777 
eHi-C support  778 
fvascular expression  779 
gnearest to lead SNP 780 
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Table 2: Association results for new independent secondary variants identified at (a) validated novel loci and (b) previously reported blood 781 
pressure loci from either UK Biobank-GWAS or exome discovery. All listed secondary variants were validated in the replication meta-analyses 782 
and passed the conditional test for independence from the (a) sentinel novel variant from Table 1, or (b) previously reported SNVs (see 783 
Supplementary Tables 8 and 10). 784 
 785 
Secondary SNV in the locus     UK Biobank discovery Replication Combined 
Locus Chr Pos rsID EA Trait INFO EAF Beta SE P Beta SE P N Beta SE P 
(a) Validated novel loci from UK Biobank GWAS 
NADK-CPSF3L 1 1254436 rs1886773 A PP 0.99 0.03 -0.743 0.13 2.0x10-8 -0.481 0.15 1.0x10-3 233,789 -0.625 0.10 1.9x10-10 
RP4-710M16.1-PPAP2B 1 56938218 rs6588634 T PP 0.99 0.89 0.403 0.08 2.1x10-7 0.270 0.07 4.7x10-5 329,029 0.326 0.05 1.0x10-10 
FN1 2 216245694 rs34923683 A PP 1.00 0.02 0.837 0.15 4.8x10-8 0.432 0.16 7.7x10-3 285,653 0.646 0.11 6.8x10-9 
TP53-SLC2A4 17 7185062 rs5417 A DBP 0.99 0.57 0.207 0.04 2.1x10-7 0.207 0.04 1.1x10-7 319,299 0.207 0.03 1.1x10-13 
KCNH4-HSD17B1 17 40709867 rs138643143 A PP 0.85 0.07 0.539 0.10 1.4x10-7 0.420 0.15 5.8x10-3 229,161 0.502 0.08 3.3x10-9 
(b) Previously reported loci 
UK Biobank GWAS                           
RNF207 1 6683240 rs14057 A SBP 0.99 0.35 -0.394 0.07 7.5x10-8 -0.235 0.06 2.0x10-4 329,584 -0.303 0.05 2.5x10-10 
FIGN-GRB14 2 165513065 rs34271465* D SBP 1.00 0.41 -0.370 0.07 1.9x10-7 -0.277 0.06 6.9x10-6 328,486 -0.317 0.05 9.9x10-12 
ENPEP 4 111431444 rs33966350* A SBP 1.00 0.01 1.742 0.31 2.6x10-8 1.525 0.41 1.8x10-4 216,630 1.661 0.25 2.1x10-11 
GUCY1A3-GUCY1B3 4 156406054 rs146853253* D PP 0.99 0.16 0.457 0.06 1.7x10-12 0.212 0.06 1.4x10-4 322,302 0.316 0.04 6.9x10-14 
EBF1 5 158220193 rs31864 A PP 0.99 0.55 0.307 0.05 1.9x10-10 0.132 0.04 1.5x10-3 326,557 0.206 0.03 5.5x10-11 
EBF1 5 158448401 rs888987 C DBP 0.96 0.37 0.208 0.04 4.4x10-7 0.111 0.04 7.1x10-3 311,814 0.160 0.03 4.3x10-8 
PDE3A 12 19979881 rs10841376 C SBP 0.99 0.76 0.261 0.08 1.6x10-3 0.362 0.07 5.1x10-7 327,370 0.319 0.05 4.5x10-9 
PDE3A 12 20230639 rs10770612 A PP 1.00 0.80 0.378 0.06 2.5x10-10 0.259 0.05 1.8x10-6 311,586 0.313 0.04 6.9x10-15 
PDE3A 12 20368269 rs60691990* T DBP 0.98 0.65 0.344 0.04 1.4x10-16 0.223 0.04 7.4x10-8 323,722 0.283 0.03 5.0x10-22 
TBX5-TBX3 12 115928440 rs10850519* C DBP 0.99 0.30 -0.244 0.04 1.4x10-8 -0.188 0.04 4.7x10-6 327,837 -0.214 0.03 5.1x10-13 
MYH6 14 23761094 rs12050260 T PP 0.97 0.35 0.261 0.05 2.9x10-7 0.132 0.05 4.1x10-3 304,390 0.190 0.03 2.6x10-8 
FURIN-FES 15 91427692 rs138682554 A SBP 0.85 0.03 1.274 0.23 5.1x10-8 0.695 0.21 8.8x10-4 279,876 0.952 0.16 9.8x10-10 
HOXB7 17 46874272 rs585736 A PP 1.00 0.03 0.712 0.13 7.8x10-8 0.517 0.13 4.1x10-5 301,845 0.609 0.09 2.5x10-11 
INSR 19 7258405 rs11671314 C SBP 0.94 0.13 0.532 0.11 8.3x10-7 0.344 0.13 6.2x10-3 253,103 0.452 0.08 3.4x10-8 
JAG1 20 10669188 rs2206815 A PP 0.98 0.50 -0.432 0.05 3.9x10-19 -0.247 0.04 2.7x10-9 324,088 -0.326 0.03 4.7x10-25 
JAG1 20 10767811 rs1040922 T DBP 0.99 0.28 -0.344 0.04 3.8x10-15 -0.156 0.04 1.8x10-4 325,879 -0.245 0.03 4.2x10-16 
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PREX1 20 47411149 rs80346118 A DBP 0.99 0.15 -0.305 0.06 3.1x10-8 -0.243 0.05 5.6x10-6 327,614 -0.273 0.04 1.1x10-12 
CRYAA-SIK1 21 44720890 rs79094191 T DBP 0.98 0.96 -0.691 0.10 3.9x10-11 -0.408 0.12 4.4x10-4 284,734 -0.564 0.08 3.8x10-13 
UK Biobank exome                           
ST7L-CAPZA1-MOV10 1 113456546 rs1049434* A DBP 1.00 0.44 -0.175 0.04 9.7x10-6 -0.131 0.03 1.1x10-5 264,717 -0.147 0.02 6.6x10-10 
CDH17 8 95264265 rs138582164 A PP 0.78 0.001 5.199 0.99 1.3x10-7 2.620 0.73 3.2x10-4 226,592 3.529 0.59 1.7x10-9 
 786 
Locus: For (a) the locus name from Table 1 for the nearest annotated gene, (b) the name of the previously reported blood pressure locus; Pos: build 37; EA: effect allele; 787 
Trait: the validated trait with most significant association in the combined meta-analysis; INFO: imputation quality score; EAF: effect allele frequency from discovery data in 788 
UK Biobank; Beta: effect estimate from linear regression; SE: Standard Error of effect estimate; P: P-value of association; N: total sample size analysed; (Note: within the UK 789 
Biobank discovery analysis the sample size was N=140,882/140,886 for systolic and pulse pressure / diastolic pressure.) The variants with * denotes secondary signals 790 
which are in LD (r2 ≥ 0.2) with secondary signals which have been published since the time of our study10,11 791 
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Figure 1: Study design schematic for discovery and validation of novel loci. N: sample size; QC: 792 
Quality Control; PCA: Principal Component Analysis; BP: blood pressure; SBP: systolic BP; DBP: 793 
diastolic BP; PP: pulse pressure; SNVs: single nucleotide variants; BMI: body mass index; UKB: 794 
UK Biobank; UKBL: UK BiLEVE; GWAS: Genome-wide association study; MAF: Minor Allele 795 
Frequency; P: P-value; LD: Linkage Disequilibrium; 1000G: 1000 Genomes. UKBBvsUKBL: a 796 
binary indicator variable for UK Biobank vs UK BiLEVE to adjust for the different genotyping 797 
chips 798 
 799 
 800 
 801 
  802 
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Figure 2: UK Biobank GWAS discovery Venn diagram of 107 validated novel loci showing 803 
concordance of significant associations across the three blood pressure phenotypes for the 804 
107 novel sentinel variants (Table 1) from both the GWAS and exome analyses, according to 805 
genome-wide significance in the combined meta-analysis. The locus names labelled within 806 
the Venn Diagram correspond to Table 1, and relate to the nearest annotated gene. 807 
 808 
 809 
 810 
 811 
 812 
 813 
Figure 3: Association of blood pressure loci with other traits. Plot (A) shows results for 814 
associations with other traits which were extracted from the PhenoScanner database for the 815 
sentinel novel variants from Table 1, including proxies in Linkage Disequilibrium (r
2
≥ 0.8), with 816 
genome-wide significant associations (P < 5×10
-8
). The loci are grouped by blood pressure 817 
traits ordered right to left according to the loci in Table 1. There are four systolic blood 818 
pressure associated loci, 14 diastolic blood pressure associated loci and nine pulse pressure 819 
associated loci with associations with other traits reported in the literature. Traits are grouped 820 
into different disease categories: “Pulse/HR” includes pulse, heart rate, pulse wave velocity 821 
and aortic stiffness traits; “CAD/CHD/MI”: Coronary Artery Disease / Coronary Heart Disease 822 
/ Myocardial Infarction; “Blood” traits: Haemoglobin levels and platelet counts; “Lipids”: LDL 823 
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and Total Cholesterol; “BMI/WHR” includes Body Mass Index, weight, obesity, waist or hip 824 
circumference, Waist-Hip-Ratio; “Menarche”: age at menarche; “Lung”: lung function (FEV1); 825 
“Alzheimer’s” traits refers to Cerebrospinal fluid levels of Alzheimer’s disease related proteins; 826 
“Cancer” includes carcinomas, neuroblastomas, bladder cancer; “Education”: years of 827 
educational attainment. 828 
Plots (B) and (C) show mouse phenotype enrichment and disease ontology enrichment, 829 
respectively, of validated novel and previously reported variants. Enrichment was performed 830 
using the GREAT tool (http://bejerano.stanford.edu/great) with the sentinel SNVs as query. 831 
 832 
 833 
 834 
 835 
  836 
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Figure 4: Distribution of Genetic Risk Score (GRS) based on previously reported and validated 837 
novel blood pressure variants and its relationship with blood pressure values, hypertension 838 
and CVD outcomes. A, Distribution of GRS in Airwave and sex-adjusted odds ratio of 839 
hypertension in age 50+ comparing each of the upper four GRS quintiles with the lowest 840 
quintile; dotted lines represent the upper 95% confidence intervals. B, Mean blood pressures 841 
and standard deviation in bracket in Airwave age 50+ across GRS quintiles. C, Distribution of 842 
GRS in UKB and sex-adjusted odds ratio of CVD, CAD and stroke comparing each of the upper 843 
four GRS quintiles with the lowest quintile; dotted lines represent the upper 95% confidence 844 
intervals. D, Count of CVD, CAD and stroke (events and deaths) across GRS quintiles in UKB 845 
participants 846 
 847 
 848 
 849 
  850 
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Figure 5: Summary of novel gene cardiovascular expression. Genes are shown on the basis of 851 
their tissue expression and supporting evidence summarised in Supplementary Table 14, 852 
based on Knockout (KO) phenotype, previously reported blood pressure biology or a strong 853 
functional rationale: eQTL (expression Quantitative Trait Loci), nsSNV (non-synonymous SNV), 854 
Hi-C. Multiple lines of evidence indicate the central importance of the vasculature in blood 855 
pressure regulation and we thus highlight existing drugged (*) and druggable (#) targets 856 
among these genes.  Illustrations used elements with permission from Servier Medical 857 
Art: www.servier.fr/servier-medical-art. We note that some druggable genes may carry a 858 
safety liability, such as GJA1, which has known association with QT interval23 859 
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 887 
Online Methods 888 
UK Biobank data 889 
Our Genome Wide Association Study (GWAS) analysis is performed using data from the 890 
interim release of the first ~150k UK Biobank participants (Supplementary Methods)17. These 891 
consist of ~100k individuals from UK Biobank genotyped at ~800,000 single nucleotide 892 
variants (SNVs) with a custom Affymetrix UK Biobank Axiom Array chip68 and ~50k individuals 893 
genotyped with a custom Affymetrix UK BiLEVE Axiom Array chip from the UK BiLEVE study69, 894 
which is a subset of UK Biobank. SNVs were imputed centrally by UK Biobank using a merged 895 
UK10K sequencing + 1000 Genomes imputation reference panel.  896 
Quality control 897 
Following quality control (QC) procedures already carried out centrally by UK Biobank, we 898 
exclude discordant SNVs and samples with QC failures, gender discordance and high 899 
heterozygosity/missingness. We further restrict our data to a subset of individuals of 900 
European ancestry. By applying kmeans clustering to the Principal Component Analysis (PCA) 901 
data a total of N=145,315 Europeans remain. Then we use the kinship data to exclude 1st and 902 
2nd degree relatives, with N=141,647 unrelated individuals remaining. Finally we restrict our 903 
data to non-pregnant individuals with two automated BP measurements available, resulting 904 
in a maximum of N=140,886 individuals for analysis (Supplementary Methods). 905 
Phenotypic data 906 
After calculating the mean systolic and diastolic pressure values from the two blood pressure 907 
measurements, we adjust for medication use by adding 15 and 10 mmHg to systolic and 908 
diastolic pressure, respectively, for individuals reported to be taking blood pressure-lowering 909 
medication (21.4% of individuals)70. Pulse Pressure is calculated as systolic minus diastolic 910 
pressure, according to the medication-adjusted traits. Hypertension, used in secondary 911 
analyses, is defined as: (i) systolic pressure ≥ 140 mmHg, or (ii) diastolic pressure ≥ 90 mmHg, 912 
(iii) or taking blood pressure-lowering medication; otherwise individuals are classified as non-913 
hypertensive. Descriptive summary statistics are provided for all individuals, and stratified by 914 
UK Biobank vs UK BiLEVE participants (Supplementary Table 1).   915 
Analysis models 916 
For the GWAS, we perform linear regression analyses of the three (untransformed) 917 
continuous, medication-adjusted BP traits (systolic, diastolic and pulse pressure) for all 918 
measured and imputed genetic variants in dosage format using SNPTEST software71 under an 919 
additive genetic model. We carry out a similar analysis for the exome content. Each analysis 920 
includes the following covariates: sex, age, age2, body mass index, top ten PCs and a binary 921 
indicator variable for UK Biobank vs UK BiLEVE to adjust for the different genotyping chips. 922 
We also run an association analysis within UK Biobank for validated novel blood pressure SNVs 923 
and hypertension using logistic regression under an additive model with adjustments as 924 
above. There are 76,554 hypertensive cases and the 64,384 remaining participants are 925 
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treated as non-hypertensive controls. This sample size is slightly larger than the N=140,866 926 
used in the main analyses, since participants with only one blood pressure measurement, but 927 
with reported blood pressure-lowering medication, could be included as hypertensive. 928 
Previously reported variants 929 
We compile a list of all SNVs previously reported to be associated with blood pressure 930 
(Supplementary Table 12). This list includes all published SNVs which have been identified 931 
and validated from previous GWAS, CardioMetabochip and exome chip projects10-12. We 932 
augment this list to include all 34,459 SNVs in Linkage Disequilibrium (LD) with the previously 933 
reported SNVs, according to a threshold of r2 ≥ 0.2. Results for all these variants are extracted 934 
for each of the three blood pressure traits, to check previously reported blood pressure 935 
associations in the UK Biobank data, according to whether the sentinel SNV or a variant at the 936 
locus in LD (r2 ≥ 0.2) with it showed evidence of support (P < 0.01) for association with at least 937 
one of the three BP traits. 938 
Replication strategy 939 
We use three independent external data sets for replication (Supplementary Methods). First, 940 
for the GWAS analysis based on advanced 1000 Genomes imputation enhanced by UK10K 941 
data we consider SNVs with MAF ≥ 1% and perform a reciprocal replication exchange with the 942 
International Consortium of Blood Pressure (ICBP) 1000 Genomes meta-analysis (max N = 943 
150,134). The imputation strategy for ICBP 1000 Genomes meta-analysis is based on an 944 
earlier imputation grid for the 1000 Genomes project. In addition, we recruit further cohorts 945 
with 1000 Genomes data which had not contributed to the ICBP-1000 Genomes discovery 946 
meta-analysis: ASCOT-UK (N = 3,803), ASCOT-SC (N = 2,462), BRIGHT (N = 1,791), Generation 947 
Scotland (GS) (N = 9,749), EGCUT (N = 5,468), Lifelines (N = 13,292) and PREVEND (N = 3,619). 948 
This gives a total of N = 190,318 independent replication samples for the GWAS discovery. 949 
Second, because the UK Biobank and UK BiLEVE genotyping chips contain exome content, we 950 
sought replication from two blood pressure exome consortia (European exome consortium 951 
and the Cohorts for Heart and Ageing research in Genome Epidemiology – CHARGE BP exome 952 
consortium), to allow validation of coding variants and variants with lower frequency. The 953 
European exome consortium (N = 161,926) and CHARGE consortium (N = 119,792) give a total 954 
of N = 281,718 independent replication samples for the UK Biobank exome discovery. 955 
 956 
Note that the lookups for GWAS and exome discovery are distinct sets of SNVs. Loci are 957 
assigned sequentially, prioritising the primary GWAS discovery first, then considering any 958 
remaining loci with non-overlapping exome content for replication in the independent exome 959 
replication resources. 960 
 961 
Statistical criteria for replication 962 
For the GWAS discovery, there are ~9.8 million SNVs with MAF ≥ 1% and INFO > 0.1. We 963 
consider for follow-up any SNVs with P < 1x10-6 for any of the three blood pressure traits. For 964 
the exome discovery, there are 149,026 exome SNVs (Supplementary Methods) which were 965 
polymorphic with INFO > 0.1; for follow-up we consider all SNVs with MAF ≥ 0.01% and P < 966 
1x10-5. All such SNVs are annotated to loci according to both an LD threshold of r2 ≥ 0.2 and a 967 
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1Mb interval region (see Supplementary Methods), and signals are classified either as 968 
belonging to novel loci, or being potential secondary signals at previously reported loci. 969 
Selection of variants for follow-up 970 
The sentinel (most significant) SNV from each association signal is selected for follow-up, all 971 
of which are pairwise-independent by LD (r2 < 0.2). For the GWAS discovery, we check that 972 
potential lookup SNVs are covered within the ICBP-1000G replication data (Supplementary 973 
Methods). Of the 235 novel loci containing previously unreported SNVs with MAF ≥ 1%, INFO 974 
> 0.1 and P<1x10-6, 218 are covered, and similarly 100 of the 123 potential secondary SNVs at 975 
51 of the 54 previously reported BP loci are available for follow-up. For the exome discovery, 976 
by following up SNVs with MAF ≥ 0.01%, INFO > 0.1 and P < 1x10-5 across the three blood 977 
pressure traits, we carry forward for replication sentinel SNVs at 22 novel loci, and potential 978 
secondary SNVs at three previously reported loci. We produce locus zoom plots for each of 979 
the lookup variants.  980 
Replication meta-analyses 981 
The replication and combined meta-analyses are performed within METAL software72 using 982 
fixed effects inverse variance weighted meta-analysis (Supplementary Methods). The 983 
combined meta-analysis of both the UK Biobank discovery (N = 140,886) and GWAS 984 
replication meta-analysis (max N = 190,070) include a total maximum sample size of N = 985 
330,956. For the exome combined meta-analysis, we synthesize data from the UK Biobank 986 
discovery exome content (max N=140,866), with the replication dataset from both exome 987 
consortia (total max N=281,718), giving a maximum sample size of N=422,604. 988 
Validation Criteria 989 
In our study a signal is declared validated if it satisfies ALL of the following three criteria:  990 
(i) the sentinel SNV is genome-wide significant (P < 5×10-8) in the combined meta-991 
analysis for any of the three blood pressure traits;  992 
(ii) the sentinel SNV shows evidence of support (P < 0.01) in the replication meta-993 
analysis alone for association with the most significantly associated blood pressure 994 
trait from the combined meta-analysis; 995 
(iii) the sentinel SNV has concordant direction of effect between the UK Biobank 996 
discovery and the replication meta-analysis for the most significantly associated 997 
blood pressure trait from the combined meta-analysis. 998 
Secondary signals  999 
By conditional analysis within UK Biobank data we assess all validated secondary signals from 1000 
novel and previously reported loci for independence from the sentinel or previously reported 1001 
SNV, respectively (Supplementary Methods). We declare a secondary signal to be 1002 
independent of the previously reported SNV if there is less than a 1.5 fold difference between 1003 
the main association and conditional association P-values on a –log10 scale, i.e. if –log10(P) / 1004 
-log10(P_cond) < 1.5. Note that the lookup criteria already ensure that the secondary variant 1005 
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is not in LD (r2 < 0.2) with the previously reported SNV. If more than one SNV in a region is 1006 
found to be independent we undertake further rounds of iterative conditional analysis.  1007 
Lookups in non-European ancestries 1008 
As a secondary analysis, we look up 102 and 5 validated novel SNVs from the UK Biobank-1009 
GWAS and exome analyses, respectively, in non-European ancestry samples. These comprise 1010 
analysis of East Asian (N = 31,513) and South Asian (N = 33,115) ancestry data from the iGEN-1011 
BP consortium13 for the GWAS lookups, and South Asian (N = 25,937), African American (N = 1012 
21,488) and Hispanic (N = 4,581) ancestry data from the CHARGE BP exome consortium12 and 1013 
CHD+ Exome consortium11, for the exome content lookups (Supplementary Methods). We 1014 
carry out a binomial (sign) test based on the number of SNVs with consistent directions of 1015 
effect between UK Biobank and each of the non-European ancestry samples. 1016 
Monogenic blood pressure gene lookups  1017 
The UK Biobank and UK BiLEVE arrays include some rare coding variants for monogenic 1018 
disorders. We collate a list of all specific mutation variants within genes known to be 1019 
associated with monogenic blood pressure disorders22. Results from the UKB discovery 1020 
association analyses for all three blood pressure traits are extracted for any of these SNVs 1021 
directly covered within the UK Biobank dataset (Supplementary Table 13). Note that a search 1022 
of proxies did not augment the list of available variants, so results are reported for the specific 1023 
variants only. 1024 
Functional analyses 1025 
In order to prioritise associated SNVs, we use an integrative bioinformatics approach to 1026 
collate functional annotation at both the variant and gene level for each SNV within the blood 1027 
pressure loci (all SNVs in LD r2 ≥ 0.8 with the blood pressure-associated SNVs). At the variant 1028 
level we use ANNOVAR73 to obtain comprehensive functional characterisation of variants, 1029 
including gene location, conservation and amino acid substitution impact based on a range of 1030 
prediction tools including SIFT and polyphen2. All nonsynonymous variants were predicted 1031 
damaging by two or more methods.  1032 
We use the University of California Santa Cruz (UCSC) genome browser to review sequence 1033 
specific context of SNVs in relation to function, particularly in the Encyclopedia of DNA 1034 
Elements (ENCODE) dataset74. We use the UCSC table browser to annotate SNVs in ENCODE 1035 
regulatory regions.  We evaluate SNVs for impact on putative micro RNA target sites in the 3’ 1036 
un-translated regions (3’UTR) of transcripts by a query of the miRNASNP database75. We 1037 
evaluate all SNVs in LD (r2 ≥ 0.8) with our novel sentinel SNVs for evidence of mediation of 1038 
expression quantitative trait loci (eQTL) in all 44 tissues using the Genotype-Tissue Expression 1039 
(GTEx) database (www.gtexportal.org), in order to identify novel loci which are highly 1040 
expressed, and to highlight specific tissue types which show eQTLs for a large proportion of 1041 
novel loci. We further seek to identify novel loci with the strongest evidence of eQTL 1042 
associations in arterial tissue, in particular. 1043 
At the gene level, we use Ingenuity Pathway Analysis (IPA) software (IPA®,QIAGEN Redwood 1044 
City,www.qiagen.com/ingenuity) to review genes with prior links to blood pressure, based on 1045 
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annotation with the “Blood Pressure” Medline Subject Heading (MESH) term which is 1046 
annotated to 684 genes. We also use IPA to identify genes which interact with blood pressure 1047 
MESH annotated genes, and evaluate genes for evidence of small molecule druggability based 1048 
on queries of Chembl (www.ebi.ac.uk/chembl/) and Drug Gene Interaction database 1049 
(dgidb.genome.wustl.edu). 1050 
We then perform overall enrichment testing across all loci. Firstly, we use DEPICT76 (Data-1051 
driven Expression Prioritized Integration for Complex Traits) to identify highly expressed 1052 
tissues and cells within the blood pressure loci. DEPICT uses a large number of microarrays 1053 
(~37k) to identify cells and tissues where the genes are highly expressed and uses 1054 
precomputed GWAS phenotypes to adjust for co-founding sources. DEPICT provides a P-value 1055 
of enrichment and false discovery rates adjusted P-values for each tissue/cells tested.  1056 
Furthermore, to investigate regulatory regions, we employ a two tiered approach to 1057 
investigate cell type specific enrichment within DNase I sites using FORGE, which tests for 1058 
enrichment of SNVs within DNase I sites in 123 cell types from the Epigenomics Roadmap 1059 
Project and ENCODE77 (Supplementary Methods). Validated novel sentinel SNVs discovered 1060 
in our study are analysed along with previously reported SNVs and secondary signals (with P-1061 
value < 1×10-4) to evaluate the overall tissue specific enrichment of blood pressure associated 1062 
variants.  In a second analysis we use FORGE (with no LD filter) to investigate directly our 1063 
curated candidate regulatory SNVs for overlap with cell-specific DNase I signals. 1064 
GenomeRunner78 is used to search for enrichment of validated novel and previously reported 1065 
sentinel SNVs with histone modification mark genomic features (Supplementary Methods). 1066 
Relevant cardiovascular tissue expression is investigated using Fantom5 reference transcript 1067 
expression data (fantom.gsc.riken.jp/5) (Supplementary Methods).   1068 
We use IPA (IPA®,QIAGEN Redwood City,www.qiagen.com/ingenuity) to identify biological 1069 
pathways and transcriptional upstream regulators enriched for genes within the blood 1070 
pressure loci. The transcriptional upstream regulator analysis aims to identify transcription 1071 
factors, compounds, drugs, kinases and other molecules, for which the target is one of the 1072 
blood pressure genes under investigation.  1073 
We query SNVs against PhenoScanner19 to investigate trait pleiotropy, extracting all 1074 
association results with nominal significance at P < 0.05 for full reporting (Supplementary 1075 
Table 15), and then extract genome-wide significant results to highlight the validated novel 1076 
loci with strongest evidence of association with other traits (Fig. 3a). We also use the Genomic 1077 
Regions Enrichment of Annotations Tool (GREAT) to study gene set enrichment of mouse 1078 
phenotype and disease ontology terms within our validated novel and previously reported 1079 
loci, using default SNV to gene mapping settings79.    1080 
We carry out metabolomics analysis using two sets of data. First we use 1H NMR lipidomics 1081 
data on plasma from a subset of 2,000 participants of the Airwave Health Monitoring 1082 
Study80,81 (Supplementary Methods). For each replicated blood pressure-associated SNV we 1083 
ran association tests with the lipidomics data using linear regression analyses, adjusted for 1084 
age and sex. We computed significance thresholds using a permutation derived family wise 1085 
error rate (5%) to account for the high correlation structure of these data (ENT=35)82. We also 1086 
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test each replicated SNV against published genome-wide vs metabolome-wide associations 1087 
in plasma and urine using publicly available data from the “Metabolomics GWAS Server” to 1088 
identify metabolites that have been associated with variants of interest at P < 3.0 x 10-4 1089 
(Bonferroni corrected P for validated signals)25,26. 1090 
Experimental methods 1091 
We prioritise novel genes for laboratory testing on the basis of evidence for SNV function 1092 
(including coding variants, eQTLs and Hi-C interactions), biological support for relevance to 1093 
blood pressure (from literature review) and transgenic phenotype. We perform genotyping 1094 
and Quantitative Reverse-Transcription Polymerase Chain Reaction (q RT-PCR) for the 1095 
selected sentinel variants of interest using human vascular smooth muscle cells and 1096 
endothelial cells and test for expression levels (Supplementary Methods). All three SNVs were 1097 
tested using an additive model. 1098 
Genetic risk scores  1099 
First, by calculating genetic risk scores (GRS), we use the Airwave study80 data to assess the 1100 
effect in an independent cohort of the blood pressure-associated variants on blood pressure 1101 
and risk of hypertension (Supplementary Methods). This provides an estimate of the 1102 
combined effect of the blood pressure raising variants avoiding bias by “winners curse”. We 1103 
create weighted GRSs for all pairwise-independent, LD-filtered (r2 < 0.2) previously reported 1104 
variants and validated novel variants (sentinel and secondary SNVs) combined, using SNVs 1105 
available in Airwave (Supplementary Table 21). For the previously reported variants, we 1106 
weight blood pressure increasing alleles by the beta coefficients from the UK Biobank 1107 
discovery GWAS. For the novel variants, beta coefficients of the replication meta-analysis are 1108 
used as independent, unbiased weights.  1109 
For the analyses of trait variance explained, we use three trait-specific GRSs (i.e. systolic, 1110 
diastolic and pulse pressure). Each GRS includes all variants, but weights are trait-specific, 1111 
using the beta coefficients from the analysis of each of the three different blood pressure 1112 
traits, e.g. the systolic GRS is weighted by the beta coefficients from the systolic GRS. To 1113 
calculate the percent of variance for each blood pressure trait explained by its corresponding 1114 
trait-specific GRS, not accounted for by known factors, we generate the residuals from the 1115 
regression model of each trait against covariates of age, age2, sex and body mass index. We 1116 
then fit a second linear model for the trait residuals with all the variants in the GRS plus the 1117 
top 10 principal components. We calculate these percentage variance explained results 1118 
within an independent population (Airwave). 1119 
For risk score analyses we calculate a single blood pressure GRS, as the average of the systolic 1120 
and diastolic pressure GRSs. We standardize the average GRS to have mean of zero and 1121 
standard deviation of one. We assess the association of the continuous average GRS variable 1122 
with each blood pressure trait by simple linear regression. We also run a logistic regression to 1123 
examine the association of the average GRS with risk of hypertension. We perform each 1124 
analysis both with and without adjustment for sex. We test for interaction between age 1125 
(below age 50, and 50 years and above) and the effect of the GRS on blood pressure. We then 1126 
compare blood pressure levels and risk of hypertension for individuals in the top and bottom 1127 
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20% of the GRS distribution at ages 50 years and over using linear and logistic regression, 1128 
respectively. 1129 
We also assess the association of the average blood pressure GRS with cardiovascular 1130 
outcomes in the UK Biobank data, based on self-reported medical history, and linkage to 1131 
hospitalization and mortality data. We include all pairwise-independent previously reported 1132 
blood pressure variants and validated novel variants. We use logistic regression with binary 1133 
outcome variables for coronary heart disease, stroke and cardiovascular disease (see 1134 
Supplementary Methods) and GRS as explanatory variable (with and without sex adjustment).  1135 
 1136 
 1137 
URLs 1138 
FORGE (accessed 16 Aug 2016), 1139 
http://browser.1000genomes.org/Homo_sapiens/UserData/Forge?db=core 1140 
Fantom5 data (accessed 16 Aug 2016), http://fantom.gsc.riken.jp/5/ 1141 
ENCODE DNase I data (wgEncodeAwgDnaseMasterSites; accessed 20 Aug 2016 using Table 1142 
browser) 1143 
ENCODE cell type data (accessed 20 Aug 2016), 1144 
http://genome.ucsc.edu/ENCODE/cellTypes.html. 1145 
Exome chip design: 1146 
http://genome.sph.umich.edu/wiki/Exome_Chip_Design 1147 
 1148 
 1149 
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